Statement: One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days.
Primary_evidence: Outcome Measurement:    Number of Participants With Dose Limiting Toxicity (DLT)   For DLT evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0). DLTs were defined as grade 4 neutropenia persisting for more than 7 days; grade 3 or above febrile neutropenia; grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion; non-hematologic toxicity (excluding toxicity related to neutrophils, leukocytes, lymphocytes, platelets, CD4 lymphocytes, anemia, and bone marrow density) greater than or equal to grade 3 (Exceptions: Dose reduction was not required even when the following conditions were met: grade 3 nausea, vomiting, or diarrhea controllable with anti-emetic or anti-diarrheal medication and abnormal laboratory parameter not requiring treatment); and day 8 administration was delayed or skipped as a result of the subject did not meet the dosing riteria within cycle.   Time frame: Up to 3 weeks Results 1:    Arm/Group Title: E7389 With Weekly Trastuzumab   Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously weekly, with an initial dose of 4 mg/kg followed by 2 mg/kg for the remaining doses.   Overall Number of Participants Analyzed: 6   Measure Type: Number   Unit of Measure: Participants  0 Results 2:    Arm/Group Title: E7389 With Tri-weekly Trastuzumab   Arm/Group Description: Eribulin mesylate (E7389) was administered intravenously on Day 1 and Day 8 of each 3 week cycle. Trastuzumab was administered intravenously tri-weekly, with an initial dose of 8 mg/kg followed by 6 mg/kg for the remaining doses.   Overall Number of Participants Analyzed: 6   Measure Type: Number   Unit of Measure: Participants  0